Professur für Endokrinologie

Ulmenweg 18
91054 Erlangen

Publications (Download BibTeX)

Go to first page Go to previous page 1 of 3 Go to next page Go to last page

Yao, J., Garg, A., Chen, D., Capdevila, J., Engstrom, P., Pommier, R.,... Kulke, M.H. (2019). Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. Endocrine-Related Cancer, 26(4), 391-403.
Pavel, M.E., Phan, A.T., Wolin, E.M., Mirakhur, B., Liyanage, N., Pitman Lowenthal, S.,... Vinik, A.I. (2019). Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. Oncologist, 24(4), 463-474.
Thürauf, N., Bachlechner, S., Denzer-Lippmann, M., Wielopolski, J., Fischer, M., Büttner, A.,... Kornhuber, J. (2019). Grehlin concentrations correlate with hunger and craving ratings following oral ingestion of macronutrients. In CHEMICAL SENSES (pp. E55-E56). OXFORD: OXFORD UNIV PRESS.
Anthony, L., Kulke, M., Caplin, M., Bergsland, E., Oberg, K., Pavel, M.E.,... Jiang, W. (2019). Long-Term Follow Up of Patients With Carcinoid Syndrome Diarrhea Treated With Telotristat Ethyl: A Pooled Analysis of Phase 2 and 3 Trials. In PANCREAS (pp. 428-428). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
Pavel, M.E., Dromain, C., Thanh, T.X.M., & Houchard, A. (2019). Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Pts with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: Prospective, Open-label, International, Phase 2 CLARINET FORTE Study. In NEUROENDOCRINOLOGY (pp. 157-157). BASEL: KARGER.
Lamarca, A., Ronot, M., Moall, S., Crona, J., Opalinska, M., Lopez, C.,... Dromain, C. (2019). Tumour Growth Rate (TGR) in Neuroendocrine Tumours (NETs): Changes Following Systemic Treatment; the GREPONET-2 Study. In NEUROENDOCRINOLOGY (pp. 137-137). BASEL: KARGER.
Yao, J.C., Strosberg, J., Fazio, N., Pavel, M.E., Ruszniewski, P., Bergsland, E.,... Singh, S. (2018). Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). In ANNALS OF ONCOLOGY. Munich, DE: OXFORD: OXFORD UNIV PRESS.
Dillon, J., Dillon, J., Kulke, M., Warner, R., Bergsland, E., Welin, S.,... Pavel, M.E. (2018). Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome. (pp. 224-224).
Banz, S., Mellar, K., Letsch, A., Scheibenbogen, C., Pavel, M.E., & Grabowski, P. (2018). First Patient Survey about Tumor - Associated Fatigue in NEN. (pp. 59-59).
Pavel, M.E., Denecke, T., Lahner, H., Hoersch, D., Rinke, A., Koch, A.,... Raderer, M. (2018). Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study. (pp. 202-202).
Atanasov, G., Tsvetkova, ., Struecker, B., Andreou, A., Bahra, M., Prasad, .,... Pascher, A. (2018). Tumor Necrosis of Primary Malignancy Affects Survival and Outcome in Patients with Liver Metastases from Neuroendocrine Tumors. (pp. 148-148).
Crona, J., Crona, J., Lamarca, A., Ronot, M., Opalinska, M., Lopez Lopez, C.,... Dromain, C. (2018). Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study. (pp. 171-171).
Fazio, N., Carnaghi, C., Buzzoni, R., Valle, J., Valle, J., Herbst, F.,... Yao, J.C. (2018). Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials. (pp. 211-211).
Mirakhur, B., Pavel, M.E., Pommier, R.F., Fisher, G.A., Phan, A.T., Massien, C.,... Vinik, A. (2018). BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS. Endocrine Practice, 24(11), 948-962.
Lamarca, A., Crona, J., Ronot, M., Opalinska, M., Lopez Lopez, C., Pezzutti, D.,... Dromain, C. (2018). Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients' Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study. (pp. 178-178).
Chan, D.L., Yao, J.C., Carnaghi, C., Buzzoni, R., Herbst, F., Herbst, F.,... Singh, S. (2018). Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials. (pp. 151-151).
Bachlechner, S., Denzer-Lippmann, M.Y., Wielopolski, J., Fischer, M., Büttner, A., Dörfler, A.,... Thürauf, N. (2017). The Effects of Different Isocaloric Oral Nutrient Solutions on Psychophysical, Metabolic, Cognitive, and Olfactory Function in Young Male Subjects. Frontiers in psychology, 8.
Denzer-Lippmann, M., Bachlechner, S., Wielopolski, J., Fischer, M., Büttner, A., Dörfler, A.,... Thürauf, N. (2017). The Effects of a Normal Rate versus a Slow Intervalled Rate of Oral Nutrient Intake and Intravenous Low Rate Macronutrient Application on Psychophysical Function - Two Pilot Studies. Frontiers in psychology, 8.
Reinauer, C., Bollow, E., Froehlich-Reiterer, E., Laubner, K., Bergis, D., Schöfl, C.,... Holl, R.W. (2017). Polycystic Ovary Syndrome (PCOS) in Juvenile and Adult Type 1 Diabetes in a German/Austrian Cohort. Experimental and Clinical Endocrinology & Diabetes, 125(10), 661-668.
Doerffel, Y., Kullmann, F., Lammert, F., Quietzsch, D., Schöfl, C., Schuppert, F.,... Lahner, H. (2017). Extension study to the open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors. (pp. 237-238).

Last updated on 2019-24-04 at 10:22